This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Labrie, F. Articles by Candas, B. Search for Related Content PubMed PubMed Citation Articles by Labrie, F. Articles by Candas, B.

Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women

Clinical Endocrine Research Unit, Laboratory of Molecular Endocrinology, CHUL Research Center and Laval University, Quebec, Canada G1V 4G2

Address all correspondence and requests for reprints to: Prof. Fernand Labrie, Laboratory of Molecular Endocrinology, CHUL Research Center, 2705 Laurier Boulevard, Quebec, Canada G1V 4G2.

The effect of 12-month dehydroepiandrosterone (DHEA) replacement therapy has been evaluated in 14 60- to 70-yr-old women who received daily applications of a 10% DHEA cream. Vaginal epithelium maturation was stimulated by DHEA administration in 8 of 10 women who had a maturation value of zero at the onset of therapy, whereas a stimulatory effect was also seen in all three women who had an intermediate vaginal maturation index before therapy. The estrogenic effect of DHEA observed in the vagina was not observed in the endometrium, which remained atrophic in all women. Most interesting, the bone mineral density significantly increased at the hip from 0.744 ± 0.021 to 0.759 ± 0.025 g/cm² after 12 months of treatment (P < 0.05). These changes in bone mineral density were associated with a significant 20.0% decrease (P < 0.01) in plasma bone alkaline phosphatase and a 28% decrease in the urinary hydroxyproline/creatinine ratio. A 2.1-fold increase over the control value (P < 0.01) in plasma osteocalcin was concomitantly observed. The present data describe for the first time a series of medically important beneficial effects of DHEA therapy in postmenopausal women through transformation of the precursor steroid DHEA into androgens and/or estrogens in specific peripheral intracrine tissues without significant adverse effects. The stimulatory effect on the vaginal epithelium in the absence of stimulation of the endometrium is of particular interest because it eliminates the need for progestin replacement therapy. On the other hand, the stimulatory effect on bone mineral density accompanied by an increase in serum osteocalcin, a marker of bone formation, suggests stimulation of bone formation by the androgenic action of DHEA, a finding of particular interest for both the prevention and treatment of osteoporosis.

This article has been cited by other articles:

				S. P. L. Rice, N. Agarwal, H. Bolusani, R. Newcombe, M. F. Scanlon, M. Ludgate, and D. A. Rees Effects of Dehydroepiandrosterone Replacement on Vascular Function in Primary and Secondary Adrenal Insufficiency: A Randomized Crossover Trial J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 1966 - 1972. [Abstract] [Full Text] [PDF]

				E. P Weiss, K. Shah, L. Fontana, C. P Lambert, J. O Holloszy, and D. T Villareal Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1459 - 1467. [Abstract] [Full Text] [PDF]

				E. M. Gurnell, P. J. Hunt, S. E. Curran, C. L. Conway, E. M. Pullenayegum, F. A. Huppert, J. E. Compston, J. Herbert, and V. K. K. Chatterjee Long-Term DHEA Replacement in Primary Adrenal Insufficiency: A Randomized, Controlled Trial J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 400 - 409. [Abstract] [Full Text] [PDF]

				A Hartkamp, R Geenen, G L R Godaert, H Bootsma, A A Kruize, J W J Bijlsma, and R H W M Derksen Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial Ann Rheum Dis, January 1, 2008; 67(1): 91 - 97. [Abstract] [Full Text] [PDF]

				L. Wang, Y.-D. Wang, W.-J. Wang, Y. Zhu, and D.-J. Li Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor J. Mol. Endocrinol., April 1, 2007; 38(4): 467 - 479. [Abstract] [Full Text] [PDF]

				K. Aizawa, M. Iemitsu, S. Maeda, S. Jesmin, T. Otsuki, C. N. Mowa, T. Miyauchi, and N. Mesaki Expression of steroidogenic enzymes and synthesis of sex steroid hormones from DHEA in skeletal muscle of rats Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E577 - E584. [Abstract] [Full Text] [PDF]

				P. Kocis Prasterone Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2201 - 2210. [Abstract] [Full Text] [PDF]

				K. S. Nair, R. A. Rizza, P. O'Brien, K. Dhatariya, K. R. Short, A. Nehra, J. L. Vittone, G. G. Klee, A. Basu, R. Basu, et al. DHEA in Elderly Women and DHEA or Testosterone in Elderly Men N. Engl. J. Med., October 19, 2006; 355(16): 1647 - 1659. [Abstract] [Full Text] [PDF]

				N. Tellez, M. Comabella, E v. Julia, J. Rio, M a. Tintore, L. Brieva, C. Nos, and X. Montalban Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone Multiple Sclerosis, August 1, 2006; 12(4): 487 - 494. [Abstract] [PDF]

				C. M. Jankowski, W. S. Gozansky, R. S. Schwartz, D. J. Dahl, J. M. Kittelson, S. M. Scott, R. E. Van Pelt, and W. M. Kohrt Effects of Dehydroepiandrosterone Replacement Therapy on Bone Mineral Density in Older Adults: A Randomized, Controlled Trial J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2986 - 2993. [Abstract] [Full Text] [PDF]

				F Labrie Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355. [Abstract] [Full Text] [PDF]

				F Labrie, V Luu-The, A Belanger, S-X Lin, J Simard, G Pelletier, and C Labrie Is dehydroepiandrosterone a hormone? J. Endocrinol., November 1, 2005; 187(2): 169 - 196. [Abstract] [Full Text] [PDF]

				L.M. Rivera-Woll, M. Papalia, S.R. Davis, and H.G. Burger Androgen insufficiency in women: diagnostic and therapeutic implications Hum. Reprod. Update, September 1, 2004; 10(5): 421 - 432. [Abstract] [Full Text] [PDF]

				K. K. Dhatariya and K. S. Nair Dehydroepiandrosterone: Is There a Role for Replacement? Mayo Clin. Proc., October 1, 2003; 78(10): 1257 - 1273. [Abstract] [PDF]

				M. Leblanc, C. Labrie, A. Belanger, B. Candas, and F. Labrie Bioavailability and Pharmacokinetics of Dehydroepiandrosterone in the Cynomolgus Monkey J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4293 - 4302. [Abstract] [Full Text] [PDF]

				J. E. Morley and H. M. Perry III Androgens and Women at the Menopause and Beyond J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M409 - 416. [Full Text] [PDF]

				F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.-X. Lin, and G. Pelletier Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone Endocr. Rev., April 1, 2003; 24(2): 152 - 182. [Abstract] [Full Text] [PDF]

				C. M. Gordon, E. Grace, S. J. Emans, H. A. Feldman, E. Goodman, K. A. Becker, C. J. Rosen, C. M. Gundberg, and M. S. LeBoff Effects of Oral Dehydroepiandrosterone on Bone Density in Young Women with Anorexia Nervosa: A Randomized Trial J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4935 - 4941. [Abstract] [Full Text] [PDF]

				G. Johannsson, P. Burman, L. Wiren, B. E. Engstrom, A. G. Nilsson, M. Ottosson, B. Jonsson, B.-A. Bengtsson, and F. A. Karlsson Low Dose Dehydroepiandrosterone Affects Behavior in Hypopituitary Androgen-Deficient Women: A Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2046 - 2052. [Abstract] [Full Text] [PDF]

				A. J. Kahn and B. Halloran Dehydroepiandrosterone Supplementation and Bone Turnover in Middle-Aged to Elderly Men J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1544 - 1549. [Abstract] [Full Text] [PDF]

				W. Arlt, F. Callies, I. Koehler, J. C. van Vlijmen, M. Fassnacht, C. J. Strasburger, M. J. Seibel, D. Huebler, M. Ernst, M. Oettel, et al. Dehydroepiandrosterone Supplementation in Healthy Men with an Age-Related Decline of Dehydroepiandrosterone Secretion J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4686 - 4692. [Abstract] [Full Text] [PDF]

				S. S. C. Yen Dehydroepiandrosterone sulfate and longevity: New clues for an old friend PNAS, July 17, 2001; 98(15): 8167 - 8169. [Full Text] [PDF]

				P. J. Hunt, E. M. Gurnell, F. A. Huppert, C. Richards, A. T. Prevost, J. A. H. Wass, J. Herbert, and V. K. K. Chatterjee Improvement in Mood and Fatigue after Dehydroepiandrosterone Replacement in Addison's Disease in a Randomized, Double Blind Trial J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4650 - 4656. [Abstract] [Full Text]

				N. Tagawa, J. Tamanaka, A. Fujinami, Y. Kobayashi, T. Takano, S. Fukata, K. Kuma, H. Tada, and N. Amino Serum Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, and Pregnenolone Sulfate Concentrations in Patients with Hyperthyroidism and Hypothyroidism Clin. Chem., April 1, 2000; 46(4): 523 - 528. [Abstract] [Full Text] [PDF]

				W. Arlt, F. Callies, J. C. van Vlijmen, I. Koehler, M. Reincke, M. Bidlingmaier, D. Huebler, M. Oettel, M. Ernst, H. M. Schulte, et al. Dehydroepiandrosterone Replacement in Women with Adrenal Insufficiency N. Engl. J. Med., September 30, 1999; 341(14): 1013 - 1020. [Abstract] [Full Text] [PDF]

				W. Oelkers Dehydroepiandrosterone for Adrenal Insufficiency N. Engl. J. Med., September 30, 1999; 341(14): 1073 - 1074. [Full Text]

				R F van Vollenhoven, J L Park, M C Genovese, J P West, and J L McGuire A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus Lupus, March 1, 1999; 8(3): 181 - 187. [Abstract] [PDF]

				S. Gingras, R. Moriggl, B. Groner, and J. Simard Induction of 3{beta}-Hydroxysteroid Dehydrogenase/{Delta}5-{Delta}4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13 Mol. Endocrinol., January 1, 1999; 13(1): 66 - 81. [Abstract] [Full Text]

				DHEA: A Novel Treatment for Osteoporosis? Journal Watch Women's Health, November 1, 1997; 1997(1101): 15 - 15. [Full Text]